Table 1 Baseline characteristics at the start of treatment

Number of patients: N (%)

7 (25%)

21 (75%)

Age (years)^a

24 (8)

33 (7)

Male sex: N (%)

5 (71.4%)

19 (90.5%)

Mean length of stay in Spain (months)^a

11 (72)

69 (28)

Co-morbidities

None

Coinfection with S. mansoni (2 patients) Fatty liver (1 patient)

ALT (IU/L)^a

84 (61)

64.5 (119)

AST (IU/L)^a

62 (26)

56.5 (93)

GGT (IU/L)^a

30 (41)

48.5 (34)

ALP (IU/L)^a

104 (66)

92 (35)

Total bilirubin (mg/dL)^a

0.4 (0.2)

0.66 (0.93)

Platelets × 10³ μL^a

204 (97)

168.5 (111)

Prothrombin time (%)^a

78 (18)

90.5 (20.3)

Alpha-fetoprotein (ng/mL)^a

4.6 (3.6)

2.5 (1.4)

HBV-DNA (log IU/mL)^a

7.23 (5.23)

5.28 (6.26)

FIB- 4 score^a

0.8 (1.8)

1.5 (0.9)

APRI score^a

0.9 (1.2)

1 (1.7)

Chosen treatment

Tenofovir (7 patients)

Tenofovir (17 patients) Entecavir (4 patients)